Study Finds Low Nephrology Referral Rate for High-Risk CKD
Even patients at the highest risk for kidney failure had inadequate nephrology referral, a study found.
Chronic Kidney Disease
Paxlovid Use for COVID-19 May Be Feasible in Advanced CKD
Nirmatrelvir/ritonavir is not current recommended for patients with CKD stage 4 or 5, but low-dose regimens could avoid adverse events, according to the authors of a recent editorial.
Ultra-Processed Foods May Up CKD Risk
Sugar-sweetened beverages are a frequently consumed ultra-processed food group.
Frequent Nut Consumption Linked With Lower CKD Risk
Nutritional therapy is an essential part of CKD management.
Excessive Body Weight Lessens the Efficacy of Vitamin D Supplements
A round up of studies suggests it is difficult to increase serum total 25-hydroxyvitamin D levels enough to effectively lower elevated parathyroid hormone (PTH) levels in overweight patients with chronic kidney disease.
Positive Efficacy Findings Prompt Early Stop of Empagliflozin CKD Trial
The EMPA-KIDNEY study enrolled more than 6600 patients with CKD attributable to a wide range of underlying causes.
More Data Needed to Make Decision on Bardoxolone in Alport Syndrome
The CRL stated that the application for bardoxolone could not be approved in its current form due to a lack of data supporting claims of slowing kidney function loss and reducing kidney failure progression.
SGLT2 Inhibitors Underprescribed for Chronic Kidney Disease
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
Chlorthalidone Safe, Effective for Treating Hypertension in Advanced CKD
In a study of patients with stage 4 chronic kidney disease and poorly controlled blood pressure, chlorthalidone significantly decreased systolic blood pressure compared with placebo.
Urate-Degrading Enzyme Fast Tracked for Hyperuricemia With Gout and CKD
ALLN-346 is an investigational, first-in-class, nonabsorbed, orally-administered enzyme that breaks down urate in the gastrointestinal tract.
- Loading...
Loading...
Next post in News
Loading... 
Loading...